The p53 gene is located on chromosome 17pl3.1 and is thought to act as a tumour suppressor. ' It is involved in the regulation of cell proliferation by stimulating the transcription of other specific cell cycle control genes. 2 Normally, cells with wild type p53 are able to delay progression from the G, to the S phase of the cell cycle while abnormal DNA is repaired. Cells with the inactivated, stabilised or mutant p53 protein cannot, and thus the replication of abnormal DNA is not prevented. Consequently, inactivation of wild type p53 gene product represents the most common genetic alteration in human carcinogenesis3-5 and its overexpression, as detected by immunohistochemistry, has been proposed to indicate a worsened prognosis in some malignancies.'
Although the exact sequence of molecular events has not been elucidated fully, loss of p53 function is believed to play an important role in the pathogenesis of carcinomas of the uterine cervix,9 where it has been shown that the p53 gene product may be inactivated in three principal ways: after (1) somatic point mutation10; (2) loss of heterozygosity"; and (3) following human papillomavirus (HPV) infection, as the viral oncoprotein E6 is known to bind to, stabilise and ultimately degrade wild type p53. '2 In this study, we have used a mouse monoclonal antibody (DO-7) to examine the overexpression of the p53 gene product in stage IB/IIA cervical carcinomas and have correlated our findings with lymph node status and clinical outcome in order to assess the value of p53 as a prognostic indicator.
Methods
Eighty two cases of FIGO stage IB/IIA cervical carcinoma, which had been treated by Wertheim's hysterectomy without prior radiotherapy, were selected from the files of the Department of Reproductive Pathology at St Mary's Hospital, Manchester, UK.
The tissue had been fixed in formalin, routinely processed and embedded in paraffin wax. The carcinomas were typed according to the criteria of Buckley and Fox'3 using haematoxylin and eosin stained sections and periodic acid Schiff/alcian blue staining, with and without diastase predigestion.
A microwave antigen retrieval method was used and sections were irradiated at 750 W for 20 minutes in 1 litre of citrate buffer (pH 6.0). For immunohistochemical staining, sections were dewaxed in xylene and a standard avidin biotin immunoperoxidase technique was applied. The sections were first incubated with normal goat serum at room temperature for 20 minutes, to reduce background staining, and then with anti-p53 mouse monoclonal antibody, DO-7 (Novocastra Laboratories, Newcastle upon Tyne, UK), diluted 1 in 100 in phosphate buffered saline at room temperature for 60 minutes. A colorectal adenocarcinoma with known overexpression of the p53 gene product was used as a positive control. Negative controls, involving substitution of the primary antibody with rabbit serum, were included for all cases. Figure 1 Positive nuclear stainingfor p53 in a well differentiated adenocarcinoma of the uterine cervix. No association was found between p53 overexpression and cervical carcinoma overall, the individual tumour subtypes, lymph node status or clinical outcome (table 2).
Discussion
The pathogenesis of carcinoma of the uterine cervix is thought to occur through a multistep process but further work is still required to clarify the exact mechanism. Attention has been focused on a number of possible cofactors including cigarette smoking, '5 immunodeficiency,'5 HLA subtypes," certain HPV subtypes,'7 and the proposed tumour suppressor gene p53,'8 as loss ofp53 function is the commonest genetic alteration involved in human malignancies.
The mouse monoclonal antibody DO-7 was chosen to examine p53 overexpression in uterine cervical carcinoma as it had been demonstrated to be the most specific and sensitive antibody directed against p53 protein when used on paraffin wax embedded tissue."9 p53 gene product has been shown to be overexpressed in cervical carcinoma as a whole and in its three main tumour subtypes to varying extents. 20 We were able to demonstrate p53 immunoreactivity in those areas of CIN III adjacent to invasive components, as has been described,27 but foci of CGIN and the normal epithelium included were negative. Holm et af20 found all grades of CIN and CGIN to be negative for p53 and suggested that alteration in p53 protein expression is not an early event in the pathogenesis of cervical neoplasia. Bosari et at27 observed that the "distribution of p53-immunoreactive cells paralleled the extension of dysplastic changes in the squamous epithelium" and suggested that p53 immunoreactivity may precede the development of tumours with a fully malignant and invasive phenotype. The presence of focal positive cells in an otherwise negative tumour may be due to increased p53 expression in cells undergoing DNA repair.28 Another explanation is alteration in mdm-2 gene expression.29 Wild type p53 is known to be bound by mdm-2 oncogene product in vitro and it is possible that overexpression of mdm-2 has resulted in accumulation of detectable p53 gene product.
The degradation of the p53 gene product after binding to the E6 viral protein in cells infected with high risk HPV subtypes may play a fundamental role in the development of cervical carcinoma.'2 It may therefore be considered a deficiency of this study that HPV analyses were not performed. found that 55% (51/92) of carcinomas were positive, but p53 protein expression was only detected in less than 5% (45/51) of the tumour cells in the majority of cases. As false tumour positivity does occur33 and there is a close relation between high levels of p53 overexpression and neoplasia,34 the validity of such observations based on results from tumours with only a small number of positive cells is difficult to assess.
These differences in interpretation highlight the problem of correlating results from different immunohistochemical studies involving antibodies directed against p53. As protocols have not been standardised, it is perhaps not possible to draw conclusions from comparisons of studies where the tumour stages, antibodies, fixation processes, antigen unmasking techniques, the determination of tumour cell positivity qualitatively and quantitatively, and statistical analysis have varied considerably.
In a recent review of the value of p53 overexpression as an indication of poor prognosis in human malignancies, cluded that while p53 is of undisputed importance in our understanding of oncogenesis and neoplasia, it is probably only a weak prognostic factor; observations in keeping with our findings. The p53 protein does indeed seem to play a pivotal role in the pathogenesis of carcinoma of the cervix but, despite the relatively small numbers involved in this series, there is no evidence to suggest that its overexpression may be useful as a prognostic indicator. Traditional parameters such as tumour size and lymph node status'4 still seem to be the most important determinants of prognosis in carcinoma of the uterine cervix.
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